Theodoros Karantanos

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Journal: Leukemia & lymphoma

Published: February 15, 2026

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Journal: Haematologica

Published: February 15, 2026

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Journal: The Journal of clinical investigation

Published: February 03, 2026

Breaking through the azacitidine plateau?-venetoclax in high-risk myelodysplastic syndrome.

Journal: Annals of translational medicine

Published: February 02, 2026

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

Journal: Blood advances

Published: December 11, 2025

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

Journal: Blood advances

Published: December 11, 2025

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Journal: Research square

Published: November 24, 2025

Molecular and Clinical Insights into TP53-Mutated MDS and AML.

Journal: International journal of molecular sciences

Published: September 28, 2025

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Journal: bioRxiv : the preprint server for biology

Published: September 02, 2025

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.

Journal: Leukemia research

Published: June 25, 2025

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Journal: The Journal of clinical investigation

Published: June 12, 2025

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.

Journal: Blood cancer journal

Published: June 08, 2025

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Breaking through the azacitidine plateau?-venetoclax in high-risk myelodysplastic syndrome.

Breaking through the azacitidine plateau?-venetoclax in high-risk myelodysplastic syndrome.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Molecular and Clinical Insights into TP53-Mutated MDS and AML.

Molecular and Clinical Insights into TP53-Mutated MDS and AML.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.